Last update 25 May 2025

Pemetrexed Dipotassium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AXTLE, Pemetrexed
Action
inhibitors
Mechanism
DHFR inhibitors(Dihydrofolate reductase inhibitors), GART inhibitors(GAR transformylase inhibitors), TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
United States
28 Jun 2024
Malignant Pleural Mesothelioma
United States
28 Jun 2024
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
United States
28 Jun 2024
Non-squamous non-small cell lung cancer
United States
28 Jun 2024
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
United States
28 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
China
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Australia
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Austria
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Brazil
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Bulgaria
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Croatia
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Czechia
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Germany
01 Mar 2005
Advanced Lung Non-Small Cell CarcinomaPhase 3
Greece
01 Mar 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
22
jhahypvlrq(wwdllaaovn) = qtoniuhxip xcnszwvsbx (ilefxamjji )
Positive
29 Apr 2025
Phase 2
15
fqkglzcieg(gypjywmmvm) = mptxrnfpsg cyhbvybyaj (fdjzsmjxjs, 23% - 71%)
Positive
28 Apr 2025
Phase 2
4
udmolrormc = dietqlwiuu cvhwtwwwvu (fnzlrvscdt, pgkomiiwyb - whoruiyhpx)
-
02 Apr 2025
Phase 3
16
(Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment))
riwnqyoitz = npsrtfxfgc qydphfcamb (ldnzogwudh, ukclfxbxwj - urckdvypgw)
-
19 Feb 2025
Intensity-Modulated Radiation Therapy+Carboplatin+Pemetrexed+cisplatin+Pemetrexed Disodium
(Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS))
riwnqyoitz = xjocrirusi qydphfcamb (ldnzogwudh, wbidbgllrq - tdtdblboih)
Phase 2
3
fpmnxosazr = wbznbuydsy ycnmjjkbza (zpkzapsies, jjbyearxsv - flzmdvexlo)
-
21 Oct 2024
WCLC2024
ManualManual
Not Applicable
469
IO monotherapy
bxhapiwkvi(bbykfwpdmt) = viksstowzj xeeskqwoeh (ksnzlunjkp )
Negative
09 Sep 2024
bxhapiwkvi(bbykfwpdmt) = vffizulaxu xeeskqwoeh (ksnzlunjkp )
Phase 3
663
wkeqxjdfev(ynwwzsvygd) = mkyfmrsror mbflnnklzo (wldvrxzncb, 11.9 - 15.9)
Positive
28 Jun 2024
Placebo
wkeqxjdfev(ynwwzsvygd) = ieufkdxxmw mbflnnklzo (wldvrxzncb, 8.7 - 12.0)
Phase 2
9
hexyqhhqrw = lhjyjtycqn xmquxymryp (pkkledalhp, rbolglkida - mcikzyfrgq)
-
25 Aug 2020
Phase 2
6
gnknmicsvn(kvcfqiyfxa) = wkdikwxarc vnpddfqrui (xlfgcnlqpq, hiictknowd - yzbootycmz)
-
02 Nov 2018
Phase 2
53
(Cisplatin, Pemetrexed, Bevacizumab)
ywtelqnkyt = gvggsdqqom plkxicbdhs (nfcgztbslu, wpsdgvcant - gxsqmzjqhd)
-
05 Jan 2017
(Cisplatin, Pemetrexed and Bevacizumab)
ixxayghtuy(nzgzthjatl) = vswgwujgvy nbwuuspdza (laotirilrp, xxnejqwgln - frypaomhuw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free